Veru (VERU) investor relations material

Company overview and business model

• Focuses on developing novel medicines for cardiometabolic and inflammatory diseases, with two late-stage drug candidates: enobosarm (for obesity and body composition) and sabizabulin (for chronic inflammation in atherosclerotic cardiovascular disease).

• Originally incorporated in Wisconsin in 1971, with principal executive offices in Miami, Florida.

Financial performance and metrics

• As of April 6, 2026, the closing price of common stock was $2.40 per share.

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $38.5 million, based on 14,480,292 shares at $2.66 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, R&D, clinical trials, marketing, drug development (including with partners), acquisitions, operating expenses, and legal proceedings.

• Pending use, proceeds will be invested in short- and medium-term, interest-bearing obligations or U.S. government securities.